Loading
Anvumetostat is an experimental small-molecule drug from Amgen in phase 2 trials for non-small-cell lung cancer, aimed at PRMT5 (MTAP-deleted cancers).
Anvumetostat is a small-molecule drug developed by Amgen. Its target is PRMT5 (MTAP-deleted cancers). The sponsor states: Anvumetostat (AMG 193) is an MTA-cooperative PRMT5 inhibitor, formulated as an oral film-coated tablet, studied in MTAP-deleted/null advanced NSCLC and other solid tumours. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in non-small-cell lung cancer. The largest, NCT05094336, plans to enrol 329 participants (actual) with primary completion expected 2026-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Anvumetostat (AMG 193) is an MTA-cooperative PRMT5 inhibitor, formulated as an oral film-coated tablet, studied in MTAP-deleted/null advanced NSCLC and other solid tumours. Connects to PRMT5 (MTAP-deleted cancers).
1.Anvumetostat slips into a pocket on PRMT5 (MTAP-deleted cancers).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Anvumetostat" OR ABSTRACT:"Anvumetostat" OR TITLE:"MTA Cooperative PRMT5 inhibitor" OR ABSTRACT:"MTA Cooperative PRMT5 inhibitor" OR TITLE:"AMG 193" OR ABSTRACT:"AMG 193") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Anvumetostat, not a curated reading list.
Shares Amgen, Non-small-cell lung cancer and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers), Non-small-cell lung cancer and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers), Non-small-cell lung cancer and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers), Non-small-cell lung cancer and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers) and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Amgen and the tag pipeline.